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Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most frequently diagnosed mitochondrial b-
oxidation defect, and it is potentially fatal. Eighty percent of patients are homozygous for a common mutation,
985ArG, and a further 18% have this mutation in only one disease allele. In addition, a large number of rare
disease-causing mutations have been identified and characterized. There is no clear genotype-phenotype correlation.
High 985ArG carrier frequencies in populations of European descent and the usual avoidance of recurrent disease
episodes by patients diagnosed with MCAD deficiency who comply with a simple dietary treatment suggest that
MCAD deficiency is a candidate in prospective screening of newborns. Therefore, several such screening programs
employing analysis of acylcarnitines in blood spots by tandem mass spectrometry (MS/MS) are currently used
worldwide. No validation of this method by mutation analysis has yet been reported. We investigated for MCAD
mutations in newborns from US populations who had been identified by prospective MS/MS-based screening of
930,078 blood spots. An MCAD-deficiency frequency of 1/15,001 was observed. Our mutation analysis shows
that the MS/MS-based method is excellent for detection of MCAD deficiency but that the frequency of the 985ArG
mutant allele in newborns with a positive acylcarnitine profile is much lower than that observed in clinically affected
patients. Our identification of a new mutation, 199TrC, which has never been observed in patients with clinically
manifested disease but was present in a large proportion of the acylcarnitine-positive samples, may explain this
skewed ratio. Overexpression experiments showed that this is a mild folding mutation that exhibits decreased levels
of enzyme activity only under stringent conditions. A carrier frequency of 1/500 in the general population makes
the 199TrC mutation one of the three most prevalent mutations in the enzymes of fatty-acid oxidation.
Introduction
In humans, medium-chain acyl-CoA dehydrogenase
(MCAD [E.C.1.3.99.3; MIM 201450]) deficiency is the
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most frequently diagnosed defect of mitochondrial b-
oxidation (Roe and Ding 2001). Disease presentation
may occur at any time of life, from the neonatal period
(Andresen et al. 1993a; Wilcken et al. 1993) to adult-
hood (Marsden et al. 1992; Ruitenbeek et al. 1995; Yang
et al. 2000). The vast majority of patients present with
metabolic crisis during the first years of life when met-
abolically challenged by fasting and/or viral illness. Usu-
ally, the phenotype includes hypoketotic hypoglycemia,
lethargy, coma, seizures, and death (Roe and Ding
2001). As many as 20% of patients die during their first
metabolic crisis (Iafolla et al. 1994). In sharp contrast,
patients diagnosed with MCAD deficiency who comply
with a treatment regimen that includes the avoidance of
fasting, a low-fat diet, and carnitine supplementation
either dramatically reduce or completely eliminate re-
current disease episodes (Iafolla et al. 1994). It is also
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recognized that undiagnosed affected individuals may
remain asymptomatic for decades and possibly through-
out life (Kelly et al. 1990; Andresen et al. 1997).
The majority (80%) of patients with clinically mani-
fested MCAD deficiency are homozygous for a common
mutation, 985ArG, and a further 18% have this mu-
tation in one disease allele (Gregersen et al. 1991; Yok-
ota et al. 1991; Pollitt and Leonard 1998). So far, no
other prevalent mutations have been identified, but a
large number of different mutations have been detected
and characterized in patients with clinical presentation
of MCAD deficiency (Andresen et al. 1997; B. S. An-
dresen, unpublished data). There is no clear correlation
between mutation type and clinical phenotype (Andre-
sen et al. 1997, and authors’ unpublished data). The
incidence of MCAD deficiency in newborns, in most
European countries, Japan, and the United States, has
been estimated by determination of carrier frequencies
for the prevalent 985ArGmutation in blood spots from
newborns. The prevalent 985ArG mutation was not
found in 1,000 Japanese newborns, and the carrier fre-
quencies were low in southern European newborns (Ta-
naka et al. 1997). High carrier frequencies (1/64–1/101)
have been determined for newborns from the north-
western part of Europe and from the white population
of the United States. The high carrier frequency in pop-
ulations of European descent suggests that MCAD de-
ficiency may be a candidate in screening of newborns.
During periods of acute metabolic decompensation,
patients with MCAD deficiency show urinary excretion
of C6–C10 dicarboxylic acids, acylglycines, and acylcar-
nitine conjugates. In particular, identification of acyl-
glycines by gas chromatography–mass spectrometry
(GC/MS) has been used for diagnosis during metabolic
decompensation (Rinaldo et al. 1988; Gregersen et al.
1994; Roe and Ding 2001). Because urinary excretion
of these metabolites is much lower when patients are
not undergoing metabolic decompensation, GC/MS is
more difficult and thus unsuitable for screening of new-
borns. Instead, the diagnosis of MCAD deficiency in
asymptomatic newborns can be made through the anal-
ysis of acylcarnitines in blood spots by tandem mass
spectrometry (MS/MS) (Van Hove et al. 1993; Ziadeh
et al. 1995; Chace et al. 1997). Because the MS/MS-
based method is fast, automatable, highly sensitive, and
specific, it has been the basis worldwide for several new-
born-screening programs for acylcarnitines and amino
acids in blood spots. To date, no validation of this
method by full mutation analysis has been reported, but
preliminary data from the first 80,371 blood spots of
newborns prospectively screened byMS/MS-based acyl-
carnitine analysis have been reported (Ziadeh et al.
1995). Analysis of these blood spots resulted in iden-
tification of nine newborns with a positive screening
result (an MCAD-deficiency frequency of 1/8,930), and
only 56% (5/9) of them were found to be homozygous
for the 985ArGmutation. Because of the small number
of positive samples and because, in the pilot study, only
one of the four prospectively identified newborns not
homozygous for the 985ArG mutation had the second
mutation identified, both the reported frequency of
1/8,930 and the ratio—only 56%—of newborns with
a positive screening result who were homozygous for
the 985ArG mutation have been the subject of much
controversy.
In the present article, we investigated the spectrum
of mutations in the MCAD gene in newborns identified
by observation of a diagnostic acylcarnitine profile by
prospective MS/MS-based screening of 1900,000 blood
spots. We investigated whether the observed mutations
were polymorphic in the general population, and we
characterized the molecular consequences of the iden-
tified missense mutations, using our Escherichia coli–
based expression system with and without co-overex-
pression of the chaperonins GroEL and GroES. Finally,
by testing 1,000 blood spots, we determined the carrier
frequency of a new common MCAD mutation that
causes a mild enzyme deficiency.
Material and Methods
MS/MS-Based Screening of Newborns
Samples for the present study were identified by MS/
MS-based screening of 930,078 blood spots collected
!72 h after birth from newborns from Pennsylvania,
Ohio, New Jersey, Illinois, Florida, and North Carolina.
The 80,371 blood spots reported in the study by Ziadeh
et al. (1995) were included in the present sample. The
acylcarnitine profiles were obtained by analysis of bu-
tylated acylcarnitines by MS/MS. Screening for MCAD
deficiency was achieved by detection of “diagnostic”
acylcarnitine profiles (i.e., elevated C6, C8, C10, and
C10:1). The analysis of all blood spots with a positive
screening result was repeated at least once. Details of
the MS/MS protocol have been described elsewhere
(Chace et al. 1997). Sixty-two newborns with patho-
logical acylcarnitine profiles consistent with MCAD de-
ficiency were prospectively detected by screening of new-
borns. Infants identified as having MCAD deficiency
were maintained on either breast milk or regular for-
mula, with no fat restriction during the 1st year of life.
Parents were instructed that their infants should avoid
prolonged fasting. Most patients were given a supple-
ment with oral carnitine, in varied doses. Only two in-
fants detected by screening of newborns died as a result
of complications associated with MCAD deficiency;
these two infants were the first in whom MCAD defi-
ciency had been detected by routine screening of new-
borns in 1992 (Ziadeh et al. 1995). None of the patients
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Figure 1 LightCycler assay for the 985ArG mutation and the
199TrC mutation. A, Assay-melting curves for the 985ArG muta-
tion, for 985A homozygotes (two samples), 985A/985G heterozygotes
(five samples), and 985G homozygotes (two samples). B, Assay-melt-
ing curves for the 199TrC mutation, for 199T homozygotes (three
samples) and a 199T/199C heterozygote (one sample).
identified since then have had any serious or permanent
sequelae. As a precaution, some patients have been ad-
mitted for glucose infusion in connection with episodes
of poor oral intake/viral illness. There have been no
deaths, seizures related to hypoglycemia, or comas. All
14 children from North Carolina have normal neuro-
logical development, to date.
Identification of Mutations in the MCAD Gene
Samples having acylcarnitine profiles indicative of
MCAD deficiency were assayed for the common
985ArG mutation. DNA was extracted from dried
blood spot, by Generations reagents (Gentra Systems).
The assay for the 985ArG mutation employed ampli-
fication in a LightCycler (Roche Molecular Systems), by
a forward primer internally labeled with LC red 640 and
an assay utilizing melting-temperature analysis and
fluorescence-resonance energy transfer (FRET). The
fluorescein–labeled probe perfectly matches the mutant
(985G) sequence and mismatches the wild-type (985A)
sequence. The details of assay for the 985ArGmutation
are described elsewhere (J. K. Smith, S. F. Dobrowolski,
M. G. Herrmann, C. T. Wittwer, personal communi-
cation); figure 1A displays typical results obtained by
this assay. Samples that had acylcarnitine profiles indic-
ative of MCAD deficiency and were either (a) identified
as being heterozygous for the 985ArG mutation or (b)
had a normal sequence in exon 11 corresponding to
cDNA position 985 were analyzed by sequencing of the
entire protein-coding region of the gene. PCR amplifi-
cations of all 12 exons—including part of the flanking
intron sequences—of the human MCAD gene were per-
formed as described elsewhere (Andresen et al. 1997),
with intron-located primers under standard conditions
in an automated Thermal Cycler 480 (Applied Biosys-
tems). Amplification of a 628-bp fragment (from 22 nt
downstream of the translation-initiation ATG to 606
nt upstream) harboring the MCAD promoter region
(Zhang et al. 1992) used nested amplification (first-
PCR primers were 5′-GGACAAGTCATAAACAGCC-
TTGGGAATACGCGGAAAGGT-3′ and 5′-CCTGCA-
GCATCGCCCGAACCCCACAGCCAT-3′, and second-
PCR primers were 5′-TGCTTTCGCTTTAGGTAGGG-
CATTTGAGAGCAA-3′ and 5′-ATCGCCCGAACCCC-
GCTGCCATGT-3′) under standard conditions, except
that 4 ml deaza dGTP was added to both amplification
reactions. PCR products were subjected to direct bidirec-
tional sequencing using DNA BigDye terminator-
sequencing kits (Applied Biosystems). Sequence reac-
tions were run on semiautomated ABI 373A and ABI
377 sequencers (Applied Biosystems).
A mutation-specific assay for the 199TrC mutation
was also developed. An asymmetric amplification using
the forward primer (5′-ATACTGACTTCATAGGACA-
TTTTTC-3′) at 0.5 mM and the reverse primer (5′-AGA-
TTTTTCCCTCTTTAAAATGTATA-3′) at 0.25 mM
produces a 198-bp fragment from the MCAD gene. A
strategy of paired hybridization probes is used to detect
the 199TrC mutation. The anchor probe (5′-LC-
red640-GGGATGATTTCCTCTCTGGCAAATTTAC-
GAGCAGT-(0P03)-3′), used at 0.2 mM, hybridizes to a
nonpolymorphic region, whereas the detection probe (5′-
CAGTTTTATCATATTCTGCAGCCA-fluorescein-3′),
used at 0.1 mM, overlays the site of the mutation. The
detection probe matches the wild-type (199T) sequence
and mismatches the mutant (199C) sequence. The assay
was validated by DNA from dried blood spots shown,
by sequence analysis, to harbor the 199TrC mutation.
Subsequently, DNA from dried blood spots from 1,000
randomly selected, anonymous newborns from the U.S.
population screened were genotyped with the assay. Fig-
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ure 1B shows profiles from specimens that are wild type
(199T) and from specimens that are heterozygous for
the 199TrC allele.
Site-Directed Mutagenesis and Expression of Wild-Type
and Mutant MCAD in E. coli JM109 Cells
The mutations 199TrC, 362CrT, 734CrT, and
928GrA were introduced by standard PCR-based site-
directed mutagenesis into the expression vector pWt
(Bross et al. 1995) using Pfu polymerase (Stratagene). A
fragment harboring the 233TrCmutation was obtained
by digesting a plasmid harboring the entire MCAD pro-
tein-coding region cloned from PCR-amplified cDNA
from a patient. The PCR products were digested with
restriction enzymes (PstI/EcoRI or EcoRI/HindIII), and
the relevant fragment was purified and cloned back into
the pWt plasmid, replacing the corresponding frag-
ment with the wild-type sequence. To confirm that no
PCR-derived errors were present in the exchanged frag-
ments, all the constructed plasmids were sequenced.
Growth—at 31C and at 37C—and disruption of bac-
terial cells and analysis by SDS-PAGE, native PAGE, and
western blot were performed essentially as described
elsewhere (Bross et al. 1993, 1995). Enzyme activity was
assayed by ferricenium ion–based analysis using octan-
oyl-CoA as substrate (Lehman et al. 1990). Measure-
ments of thermal-inactivation profiles were performed
as described elsewhere (Bross et al. 1995; Andresen et
al. 1997). The concentration of protein in E. coli JM109
cell extracts was determined by a modified Bradford
assay kit (BioRad). All experiments were performed
at least twice, with enzyme-activity measurements per-
formed in duplicate each time.
Results
MS/MS-Based Screening of Newborns
Prospective screening of newborns identified 62 blood
spots with a pathological acylcarnitine profile from
930,078 analyzed in the 8-year period from December
1, 1992, through January 31, 2001. All results with a
pathological acylcarnitine profile were verified in at least
two separate analyses of the blood spot and, in most
cases, also in a repeat blood spot specimen obtained at
a later date. This indicates a frequency in the population
screened of 1/15,001 newborns with a pathological acyl-
carnitine profile. The profiles observed were rated ac-
cording to the amounts of acylcarnitines present, and
the results are listed in table 1; a “mild” profile was
defined as an octanoylcarnitine concentration of 0.5–2.0
mmol/liter and an octanoylcarnitine:decanoylcarnitine
ratio of 2–4, and a “severe” profile was defined as an
octanoylcarnitine concentration of 12.0 mmol/liter and
an octanoylcarnitine:decanoylcarnitine ratio of 14.
Blood spots from newborns homozygous for the
985ArG mutation always showed a severe profile.
Identification of Mutations in the MCAD Gene
The 62 acylcarnitine-positive blood spots identified by
MS/MS-based screening of newborns were first tested
for the presence of the common 985ArGmutation, with
the LightCycler-based mutation-specific assay. In 60 of
these 62 newborns, at least one copy of the 985GrA
mutation could be identified: 39 (63%) were homozy-
gous for the 985ArG mutation, 21 (34%) were hetero-
zygous for it, and 2 (3%) did not harbor it at all (table
1). To search for mutations in the 25 alleles not har-
boring the 985ArG mutation, we performed PCR fol-
lowed by direct sequencing of the entire protein-coding
region and of the 5′ UTR harboring the MCAD pro-
moter. This analysis was possible for 20 of the 23 blood
spots found not to be homozygous for the 985ArG
mutation. The results of the sequence analysis are listed
in table 1. We identified a non-985ArG mutation in 17
of the 20 analyzed samples. In a sample from an African
American baby, we did not identify any mutations, and,
in blood spots from three newborns, we identified only
one mutation (the prevalent 985ArG mutation in two
of the newborns and a 734CrT mutation in the other).
In three of these four newborns, the acylcarnitine profile
repeatedly showed a pathological profile, indicating that
these newborns have a defect in MCAD but that we
failed to identify the causal mutation. The fourth case
is an apparent normal carrier with a single copy of the
734CrT mutation and had a mild acylcarnitine profile
that normalized with time. Also the newborn hetero-
zygous for the 985ArG and 351ArC mutations (table
1) had a mild acylcarnitine profile that normalized with
time; a completely normal acylcarnitine profile and nor-
mal organic acid analysis was obtained from this new-
born during an illness when he was admitted because of
high fever and poor oral intake. This indicates that the
silent mutation 351ArC is neutral and, thus, that this
newborn is to be considered only as a normal carrier
with a single copy of the 985ArG mutation.
The frequency of all identified mutations was checked
in 100 chromosomes from normal controls, by sequence
analysis of the relevant exons (exons 3–5, 7, 9, and 10,
including part of the flanking introns) from genomic
DNA. Four control samples were heterozygous for the
351ArCmutation in exon 5, showing that thismutation
is polymorphic in the general population. None of the
other sequence variations were identified in controls.
None of the newborns had any nonpolymorphic se-
quence variations in the sequenced part of the 5′ UTR.
Our sequence analysis of the 100 control chromosomes
also revealed three intronic single-nucleotide poly-
morphisms (SNPs)—IVS310T/C, IVS532G/C, and
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Table 2
SNPs and Haplotypes Obtained by Sequence
Analysis of 1100 Controls
POLYMORPHISM
NO. (%)
OF ALLELES
HAPLOTYPE
A B C
IVS310T/C: T C C
T 88 (77%)
C 26 (23%)
IVS532G/C: C G G
G 36 (33%)
C 72 (67%)
IVS622A/C: C A A
A 25 (21%)
C 95 (79%)
351A/C: A C A
A 4 (4%)
C 108 (96%)
IVS622A/C. The frequencies of these SNPs are listed
in table 2. Analysis for the three intronic SNPs and
351A/C in individuals who are homozygous for the prev-
alent 985ArG mutation, in informative families, and in
controls showed that these polymorphisms represented
only three different haplotypes. The haplotype of the
chromosome harboring the non-985ArG mutation in
the newborns is also listed in table 1. In all seven het-
erozygous individuals, the 199TrC mutation is located
on a chromosome with the same haplotype (i.e., hap-
lotype A), indicating a common origin of the 199TrC
mutant chromosome.
Because the 199TrC mutation in exon 3 was present
in as many as 7 (35%) of the 20 sequenced samples with
non-985ArGmutations, we decided to estimate the car-
rier frequency for this mutation in the general U.S. pop-
ulation. For this purpose, we developed a 199TrC mu-
tation–specific LightCycler assay. First, the assay was
used to confirm the presence of the 199TrC mutation
in the samples from newborns with a pathological acyl-
carnitine profile for whom this mutation had already
been identified by sequence analysis. Next, we tested
genomic DNA from dried blood spots from 1,000 ran-
domly selected, anonymous newborns from the U.S.
population screened by the LightCycler assay. Two sam-
ples were found to be carriers of the 199TrC mutation,
indicating that the carrier frequency may be as high as
1:500.
Evaluation of the Effect of the Identified Mutations
We identified 12 different mutations (including
985ArG) in samples from newborns; of these muta-
tions, 5—985ArG, 233TrC, 244insT, 351ArC, and
362CrT—have previously been identified in patients
with clinically manifested MCAD deficiency (B. S. An-
dresen, unpublished data), and the other 7—199TrC,
343–348del, IVS51GrA, 489TrG, IVS86GrT,
734CrT, and 928GrA—have not previously been iden-
tified in patients with a clinical phenotype. That the pa-
tient with the IVS51GrA mutation died from a met-
abolic crisis shows, however, that this mutation may
result in clinical presentation. Three of the identified
mutations—the two silent mutations, 351ArC and
489TrG, and the IVS86GrT mutation—are impos-
sible to evaluate at present. We speculate that these three
mutations and the IVS51GrA mutation affect MCAD
mRNA splicing, but it is also possible that 489TrG,
IVS86GrT, and, in particular, 351ArC are neutral
sequence variations. The IVS51GrA mutation
changes the highly conserved 1G in the splice consen-
sus sequence; and mutations at this position have, to the
best of our knowledge, always affected mRNA pro-
cessing. The 244insT mutation results in a shifted read-
ing frame from codon 57 of the mature MCAD protein,
ending with a premature termination codon 23 codons
downstream, and it thus is clearly deleterious. The
343–48del (delGly90–Cys91) could be predicted to be del-
eterious, because we have shown, by overexpression ex-
periments, that mutation of Cys91 to either tyrosine or
glycine leads to a complete lack of functional MCAD
(B. S. Andresen and S. Udvari, unpublished data). Fur-
thermore, we have, in clinically affected patients (An-
dresen et al. 1997; B. S. Andresen, unpublished data),
identified mutations that change the codon for Cys91.
To evaluate their effects, the identified missense mu-
tations were characterized by our E. coli–based expres-
sion system, with and without co-overexpression of the
chaperonins GroEL and GroES (Bross et al. 1993, 1995;
Andresen et al. 1997). Expression of the recombinant
mutant proteins Y42H (199TrC), I53T (233CrT),
T96I (362CrT), S220L (734CrT), G285R (928GrA),
and K304E (985ArG), at 31C without GroESL co-
overexpression, showed that all except Y42H exhibit a
considerably decreased enzyme activity, when compared
to the wild-type protein (fig. 2). When the GroESL chap-
eronins were co-overexpressed, the enzyme activity of
I53T, T96I, S220L, G285R, and K304E was increased,
indicating that compromised folding is part of the
molecular defect mechanism. Analysis by native PAGE/
western blotting of the lysates from the E. coli cells
expressing wild-type MCAD or the mutant proteins
showed that the amounts of tetrameric MCAD protein
formed corresponded well with the amount of enzyme
activity for all mutations except T96I, in which the
amount of tetramers was comparable to that in the wild-
type protein (results not shown). Analysis of the three-
dimensional structure of the MCAD monomer (Kim et
al. 1993) shows that T96I is located in the binding site
of the acyl moiety of the substrate, indicating that this
mutation may affect enzyme activity by interfering with
the structure of the active site. That, at 31C, the activity
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Figure 2 Enzyme activity of mutant MCAD proteins. Trans-
formed JM109 cells harboring expression plasmid encoding themature
part of either wild-type (WT) MCAD protein or one of the mutant
MCAD proteins and either the plasmid pGroESL, encoding the chap-
eronins GroEL and GroES (unshaded bars), or the control plasmid
pCaP, which lacks the GroESL chaperonin genes (shaded bars), grown
and induced as described by Andresen et al. (1997). Extracts were
investigated by measurement of enzyme activity. The designations of
the mutant are indicated below the corresponding bars;  and 
respectively indicate whether the chaperonins GroEL and GroES were
co-overexpressed. The culture temperature is indicated. MCAD en-
zyme activity in the soluble fraction was measured by the ferricenium
assay (Lehman et al. 1990). Columns represent the average from two
to five independent experiments in which enzyme-activity measure-
ments were performed in duplicate in each experiment. The vertical
lines on top of the bars indicate the ranges of the values obtained in
the experiments.
of cells overexpressing Y42H was nearly indistinguish-
able from that of cells overexpressing the wild-type pro-
tein indicates that this is a mild mutation. We therefore
repeated the overexpression experiments for this mutant
and the other mild mutations—S220L and G285R—at
37C, with K304E and the wild-type protein as refer-
ences (fig. 2). This repetition showed that, at physiolog-
ical temperature, these mutations all may lead to a
decreased enzyme activity. That the residual enzyme
activity of the Y42Hmutant enzyme at 37Cwas slightly
increased when the chaperonins GroESL were overex-
pressed and that a lower culture temperature (31C) re-
stores enzyme activity to near wild-type levels indicate
that this is a mild folding mutation. We also investigated
the thermal inactivation profiles of Y42H, S220L, and
G285R (fig. 3), in the manner elsewhere described for
K304E (Bross et al. 1995), and three other MCAD mu-
tant proteins (Andresen et al. 1997). The thermal sta-
bility of G285R was markedly lower than that of wild-
type protein, whereas the thermal stabilities of Y42H
and S220L were not significantly affected.
Discussion
The primary goal of this study was to validate, by mo-
lecular genetic methods, the MS/MS-based method rou-
tinely being used, in several countries, for screening of
newborns. Second, we wanted to determine if differences
in the biochemical phenotypes of MCAD deficiency,
monitored as an acylcarnitine profile in blood spots of
newborns, could be explained by differences in the
MCAD genotype and, thus, if a correlation between bi-
ochemical phenotype andMCAD genotype exists during
the asymptomatic period.
From 930,078 newborns screened at NeoGen Screen-
ing, we identified 62 newborns with elevated acylcar-
nitine in their blood spots that was indicative of MCAD
deficiency. This is an MCAD-deficiency frequency of
1/15,001, which is much lower than the frequency of
1/8,930 that was reported in the pilot study, in which
only 80,371 samples were studied (Ziadeh et al. 1995).
The frequency of 1/15,001 is, however, significantly
higher than previous estimates based on studies of the
985ArG carrier frequency in the United States (Mat-
subara et al. 1991; Gregersen et al. 1993). In Texas,
molecular testing of 536 blood spots of newborns in-
dicated a carrier frequency of 1/107 in a population of
diverse ethnicities (Matsubara et al. 1991); likewise,
testing of 3,595 blood spots of newborns from North
Carolina indicated a carrier frequency of 1/108 (Gre-
gersen et al. 1993). Subdivision of the blood spots tested
in North Carolina showed a carrier frequency of 1/84
in whites and a carrier frequency of 1/492 in nonwhites.
In light of the diverse ethnicities of the populations of
Pennsylvania, Ohio, Illinois, Florida, New Jersey, and
North Carolina, it is reasonable to estimate the carrier
frequency to be 1/80 in the diverse-ethnicity popu-
lation screened in the present study, indicating a
985ArG-homozygous frequency of 1/25,000. Thus, we
would expect 36–38 985ArG homozygotes in the
930,078 samples screened, and our identification of 39
985ArG homozygotes in the 62 acylcarnitine-positive
blood spots tested shows that the MS/MS-based screen-
ing method detects the expected number of 985ArG-
homozygous newborns. Moreover, this indicates that all
985ArG-homozygous newborns have a diagnostic
acylcarnitine profile in their blood spots. We therefore
conclude that the MS/MS-based screening method is
excellent for detection of individuals homozygous for
the prevalent MCAD deficiency–causing mutation
985ArG.
The proportion of the acylcarnitine-positive samples
found not to be homozygous for the prevalent 985ArG
mutation (i.e., 23 [37%] of the 62 detected) is, however,
nearly twice as high as among patients (∼20%) who
have experienced clinical symptoms of MCAD defi-
ciency (Gregersen et al. 1991; Yokota et al. 1991; Pollitt
and Leonard 1998). This skewed ratio could occur if
some of the samples that were not homozygous for the
985ArG mutation (mainly 985ArG heterozygotes)
were false positives, a possibility that was not addressed
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Figure 3 Thermal inactivation profiles of the mutant proteins Y42H, S220L, and G285R and of wild-type (WT) MCAD protein. Inves-
tigation of the thermal-inactivation profiles of the mutant proteins Y42H, S220L, and G285R and of wild-type MCAD was performed as
described elsewhere (Bross et al. 1995; Andresen et al. 1997). Lysed samples from cells overexpressing the mutant proteins were incubated for
10 min at the temperatures indicated, before MCAD enzyme activity in the soluble fraction was measured by the ferricenium assay. Each value
represents the mean of four samples, and the bars represent the ranges of the highest and lowest measurements.
in the pilot study by Ziadeh et al. (1995). So far, pre-
liminary studies have indicated that the acylcarnitine
profiles in blood spots from older children who were
either 985ArG heterozygotes or 985ArGhomozygotes
are not always clearly distinguishable (Clayton et al.
1998), whereas the situation seems to be more clear-cut
for newborns (Van Hove et al. 1993; Clayton et al.
1998). That, in the present study, we have been able to
identify two mutations in all but 4 of the 20 sequenced
samples that were not homozygous for the 985ArG
mutation strongly suggests that false positives are not
the reason for the skewed ratio. Sequencing was not
performed on three samples. In three of the four se-
quenced samples in which two mutations could not be
identified, there was a consistent elevation of acylcar-
nitines on repeated screening, and it is therefore most
likely that our lack of identification of two mutations
in these samples is caused by the mutations being lo-
cated outside the examined region of the gene. This is
further indicated by the fact that the only sample in
which we failed to identify both mutations was from
an African American. We have previously investigated
a single African American patient forMCADmutations,
and in that case we failed also to identify two disease-
causing mutations (B. S. Andresen, unpublished data).
This may indicate that an MCAD mutation exists in
African Americans that escapes detection by our
procedure.
All identified mutations except two silent mutations
and one splice mutation may be predicted to be dele-
terious. Confirmation of the enzyme defect in three new-
borns harboring silent/presumed splice mutations must
await analysis of cells by specific enzyme assay and/or
RNA/cDNA analysis. The 351ArC polymorphism is,
however, likely to be neutral, since the newborn with
the 985ArG/351ArC genotype showed a normal acyl-
carnitine profile and normal organic acids during a fe-
verish illness. Our results for E. coli expression of the
missense mutant proteins proved the deleterious nature
of all the missense mutations investigated. The results
also illustrate, as described elsewhere (Andresen et al.
1997; Bross et al. 1998), that there is considerable var-
iation in the severity of the different mutations and that
the residual enzyme activity of many of the missense
mutants may be modulated by endogenous factors, such
as the number of available chaperones and the temper-
ature. Despite this, the intrinsic severity of themutations
was reflected in the biochemical phenotype of the new-
borns and was expressed by differences in their acyl-
carnitine profile.
1416 Am. J. Hum. Genet. 68:1408–1418, 2001
Identification of a new mutation, 199TrC, in seven
of the samples was particularly interesting. Its presence
in such a high proportion of the acylcarnitine-positive
samples suggested to us that this mutation must have
a rather high carrier frequency in the general popula-
tion. We therefore developed a mutation-specific assay
and, in an analysis of 1,000 blood spots of newborns,
determined that the 199TrC mutation had a frequency
of 1/500. With a 985ArG carrier frequency of 1/80 and
a 199TrC carrier frequency of 1/500, we would expect
to detect five to six newborns with a 199TrC/985ArG
genotype when 930,078 newborns are screened—if they
all exhibit a diagnostic acylcarnitine profile. Although
the number of samples is too low to allow any firm
conclusions to be drawn, our results indicate that all
individuals with this genotype are detected. Because
the frequency of 199TrC homozygotes would be
∼1/1,000,000, it is not possible to determine, from the
present data, whether such individuals also exhibit a
diagnostic acylcarnitine profile. A carrier frequency of
1/500 makes the 199TrC mutation one of the three
most common mutations in enzymes of mitochondrial
fatty-acid oxidation. Its frequency is comparable with
that of the common 1528GrC long-chain 3-hydroxy-
acyl-CoA dehydrogenase (LCHAD) mutation (i.e.,
1/175–1/680) (Ibdah et al. 1999; den Boer et al. 2000),
which is found in 87% of alleles of patients with LCAD
deficiency. The high frequency of the 199TrCmutation
in samples from newborns with a diagnostic acylcar-
nitine profile is also illustrated by our recent identifi-
cation of a newborn (not included in this study) with
a 985ArG/199TrC genotype who was identified by
MS/MS-based screening of newborns in New England.
In addition, two newborns with this same genotype have
recently been identified in a GermanMS/MS-based new-
born-screening program (Lindner et al. 2000), indicat-
ing that it is also prevalent in populations outside the
United States. Despite this high frequency, the 199TrC
mutation has never been observed in our sample of 180
clinically affected patients who were not homozygous
for the 985ArG mutation (B. S. Andresen, unpublished
data), nor has it been reported in the literature by others.
In fact, the large proportion of samples of newborns
with the 985ArG/199TrC genotype that are detected
by the MS/MS-based screening method is sufficient to
explain the lower frequency of the 985ArG mutant
allele in this group, as compared to its frequency in the
group of patients with clinically manifested MCAD.
This, together with the fact that it is a mild missense
mutation (as judged both from our overexpression ex-
periments in E. coli and from the observation of a mild
acylcarnitine profile in the samples), makes it difficult
to evaluate the likelihood of clinical symptoms in new-
borns with the 985ArG/199TrC genotype. Likewise,
this evaluation is difficult in newborns with the other
mild mutations (i.e., G285R and S220L). We have pre-
viously shown that there is no correlation between the
severity of the mutations and the clinical phenotype in
patients (Andresen et al. 1997; B. S. Andresen, unpub-
lished data). Patients homozygous for mutations that
leave no residual enzyme activity (i.e., frameshift and
stop mutations) may remain without clinically mani-
fested disease for years (Andresen et al. 1997; B. S.
Andresen, unpublished data), whereas a patient who is
compound heterozygous for the 985ArGmutation and
a mild mutation—157CrT (R28C), which, in its mo-
lecular pathology, is similar to the 199TrC (Y42H)
mutation—may die suddenly and unexpectedly (Andre-
sen et al. 1993a). Moreover, individuals with MCAD
deficiency may present the disease inmanners other than
those usually expected (Marsden et al. 1992; Beekman
et al. 1994; Ruitenbeek et al. 1995). It could therefore
be speculated both (1) that individuals with the mild
985ArG/199TrC genotype—and, perhaps, also indi-
viduals with some of the other apparently mild geno-
types identified in the present study—may present with
clinical symptoms under circumstances other than those
usually observed in patients with MCAD deficiency and
(2) that this is the reason why no individuals with the
mild genotypes have so far been identified among pa-
tients with “classical” MCAD. So far, none of the new-
borns identified by MS/MS-based screening (except for
the two newborns described elsewhere [Ziadeh et al.
1995] who died) have had any serious or permanent
sequelae. In light of the potential morbidity of the
disease, this clearly illustrates the advantages of the
MS/MS-based newborn-screening program.
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